This lecture was part of a CME accredited symposium: 'Managing Diabetes & CVD: Is epigenetics a new way forward?' held at ESC 2017 in Barcelona on August 26, 2017
In chronic HF patients, the short-term all-cause mortality was increased in those with hypo- and hyperkalaemia, as well as in those in the lower and upper levels of the normal potassium range.
This lecture was part of a CME accredited symposium: Modern management of diabetes in cardiology: impact of SGLT2 inhibition on cardiovascular outcomes and heart failure held at ESC 2017 in Barcelona on August 28, 2017
Although midlife hypertension is more common in men, it was only associated with the risk of dementia in women, suggesting that hypertension is a modifiable risk factor for dementia in women.
a concentration of 400 pg/mL, any given concentration of NT-proBNP had a similar predictive value for adverse outcomes in HFrEF patients with and without AF.
Pooled analysis of phase II studies evaluating apabetalone suggest that this epigenetic therapeutic may yield clinical benefit for CVD patients with low HDL-C, diabetes, and elevated hsCRP levels.
In the AFFIRM study, SBP variability was inversely associated with the quality of anticoagulation control in AF patients, and increasing SBP variability was associated with a higher risk of major adverse clinical outcomes.
The phase III study evaluated rivaroxaban vs aspirin in patients with embolic stroke of undetermined source. An interim analysis indicated no benefit of the NOAC over aspirin in reducing recurrent events.
The practical clinical guidance aims to help clinicals identify very high risk patients with substantially elevated LDL-c despite treatment, who are likely to benefit most from treatment with PCSK9 inhibition
A randomized, cross-over study showed a stronger antiplatelet effect and a faster and more potent antithrombotic effect with ticagrelor than with clopidogrel in T2DM patients with stable CVD.
Prof. Neil Poulter gives a brief overview of the design and results of the LEADER CV outcomes trial with the GLP-1 agonist liraglutide.
Based on data of the large Dutch Lifelines cohort, reference values have been developed for lipid parameters.